Thermosensitive Hydrogel Composition for Sustained DFO Nanochelator Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current iron chelation therapies, such as deferoxamine (DFO), have a very short half-life requiring frequent injections or infusions, leading to poor patient compliance and adverse effects, while oral chelators cause significant side effects, and existing hydrogel formulations may be toxic.
Innovation Solution
Development of a sustained-release, injectable thermosensitive hydrogel formulation using crosslinked hyaluronic acid and Pluronic F127 to deliver DFO-NPs, providing a two-week release period for effective iron chelation therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If deferoxamine (DFO) is used for iron chelation therapy, then therapeutic efficacy is improved, but patient compliance deteriorates due to very short half-life requiring repeated injections or continuous infusions
Solution Approach 1:
The patent changes the physical and chemical parameters of DFO by formulating it as nanochelators (DFO-NPs) with specific size ranges (20-200 nm) and incorporating them into thermosensitive hydrogel matrices. This transforms DFO from a rapidly clearing small molecule into a sustained-release formulation that maintains therapeutic levels over extended periods (2 weeks or longer), thereby improving patient compliance without sacrificing efficacy
Solution Approach 2:
The patent introduces thermosensitive hydrogels as an intermediary carrier system between the administered DFO and the target iron deposits. The hydrogel acts as a reservoir that controls the release kinetics of DFO-NPs, mediating the delivery process to achieve sustained therapeutic concentrations while reducing the frequency of administrations required
2Ease of operation
If oral iron chelators (DFP or DFX) are used to improve compliance, then patient compliance is improved, but adverse effects worsen due to gastrointestinal bleeding, agranulocytosis, hepatic fibrosis, and kidney failure
Solution Approach 1:
The patent changes the route of administration parameter from oral to parenteral (subcutaneous or intravenous injection of the hydrogel formulation). This bypasses the gastrointestinal tract, eliminating the gastrointestinal side effects associated with oral chelators like DFP and DFX, while still achieving sustained therapeutic delivery through the injectable hydrogel system
Solution Approach 2:
The patent uses a biodegradable and biocompatible hydrogel formulation that degrades over time, releasing DFO-NPs as needed. The hydrogel matrix itself is designed to be transient, providing sustained release without long-term persistence in the body, thereby reducing chronic toxicity risks while maintaining compliance benefits
3Ease of operation
If polymeric hydrogels are used for sustained drug release, then compliance is improved, but toxicity worsens due to potential toxicity of polymeric hydrogels
Solution Approach 1:
The patent employs a composite hydrogel formulation combining thermosensitive polymers with crosslinked hyaluronic acid particles. This composite structure leverages the sustained-release capability of the thermosensitive hydrogel while incorporating biocompatible and biodegradable hyaluronic acid, which reduces potential toxicity and improves safety profile compared to synthetic polymeric hydrogels alone
Solution Approach 2:
The patent modifies the chemical composition parameters of the hydrogel by integrating crosslinked hyaluronic acid (with specific molecular weights and crosslinking densities) into the thermosensitive polymer matrix. This compositional change enhances biocompatibility and reduces toxicity while preserving the thermosensitive gelation properties that enable sustained release and improved compliance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel formulation achieves prolonged DFO-NP release, improving patient compliance and minimizing off-target tissue distribution, with reduced toxicity and adverse effects.
Implementation Method 1
injectable thermosensitive hydrogels have been frequently used for drug delivery because they do not require additional chemical reactions and external stresses (e.g., light or pressure) to crosslink
Data Source
AI summary
Disclosed herein are injectable hydrogel formulations prepared by integrating crosslinked hyaluronic acid into Pluronic F127 for an extended release of DFO nanochelators. Methods of manufacture and of use are also provided.